Bing Yuan, OnCusp Therapeutics CEO
January 4, 2024 09:25 AM EST
Financing
Startups
China

An­oth­er day, an­oth­er ADC: On­Cusp se­cures $100M Se­ries A from No­vo, Or­biMed and oth­ers to run PhI tri­al

Kyle LaHucik

Senior Reporter

The an­ti­body-drug con­ju­gate news keeps flow­ing: On­Cusp Ther­a­peu­tics is the lat­est to join the are­na with an over­sub­scribed $100 mil­lion Se­ries A

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times